Table 3.

Font trial: outcomes by treatment arm

	Treatment arm
Outcome	Adalimumab	Galactose	Standard	Total
Success	0	2	2	4
Failure	7	5	5	17
Total	7	7	7	21

The co-primary endpoints included: (1) Reduction in proteinuria at 6 months by ≥ 50 % of the value at the time of screening, AND (2) Estimated GFR (eGFR) at 6 months ≥ 75 % of the value at the time of randomization in those with an initial eGFR <75 mL/min/1.73 m² OR eGFR persistently ≥75 mL/min/1.73 m² in those whose renal function was ≥75 mL/min/1.73 m² at the time of randomization